Deals channel feed

I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

Last year
China

Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Last year
Pharma

Gilead won't ac­quire check­point on­col­o­gy biotech Tizona

Last year
Pharma

No­var­tis to buy Mor­phoSys for $2.9B af­ter 20 years of cre­at­ing an­ti­bod­ies with the Ger­man biotech

Last year
Pharma

Four burn­ing ques­tions about the fu­ture of the $16.5B No­vo-Catal­ent deal

Last year
Manufacturing

Up­dat­ed: No­vo Hold­ings pays $16.5B to take Catal­ent pri­vate — and sells three man­u­fac­tur­ing sites to No­vo Nordisk

Last year
Manufacturing

Un­like Mer­ck, Bris­tol My­ers to fo­cus on bolt-ons af­ter M&A spree

Last year
Pharma

No­var­tis ends li­cense agree­ment for can­cer drug with Al­lar­i­ty Ther­a­peu­tics for lack of pay­ment

Last year

Mer­ck still on the hunt for bil­lion-dol­lar deals, cit­ing Prometheus and Dai­ichi Sankyo as ex­am­ples

Last year
Pharma

Take­da wa­gers $300M on Pro­tag­o­nist’s PhI­II rare dis­ease drug

Last year

Avro­bio makes way for GPCR biotech Tec­ton­ic Ther­a­peu­tic in re­verse merg­er

Last year
Startups
Cell/Gene Tx

Cor­rect­ed: 2sev­en­ty bio sells R&D unit to Re­gen­eron for $5M up­front, cuts ad­di­tion­al staff

Last year

Gilead in­vests an­oth­er $320M in Ar­cus as part­ners re­hash their TIG­IT pact

Last year
R&D
Pharma

Roche ends KRAS deal with Hookipa Phar­ma, as biotech lays off 30% of staff

Last year
People
R&D

De­cen­tral­ized tri­als com­pa­ny Sci­ence 37 to go pri­vate in deal with di­ag­nos­tics start­up eMed

Last year
Startups

Sanofi part­ners with Syn­thekine in im­munol­o­gy race

Last year

For biotechs in the in­dus­try’s hand­ful of hot ar­eas, it’s a sell­er’s mar­ket

Last year

Arecor to re­tain In­hi­brx roy­al­ties in wake of Sanofi ac­qui­si­tion

Last year

J&J talks up $3B in deals that did­n't make head­lines in 2023

Last year
Pharma

No­vo Nordisk con­tin­ues to stack obe­si­ty pipeline, this time with Swiss ze­brafish biotech

Last year

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Last year
R&D

Neu­ro com­pa­nies are one of phar­ma's hottest M&A as­sets. But be­hind the scenes, there have been few bid­ders

Last year
Pharma

Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Last year
R&D
Pharma

Co­herus sells San­doz its Lu­cen­tis biosim­i­lar for $170M to fo­cus on on­col­o­gy as­sets 

Last year
Pharma
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times